Cargando…

A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy

OBJECTIVE: This multicenter, retrospective, observational study investigated baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer who received primary androgen deprivation therapy, using Japan Study Group of Prostate Cancer registry data. METHODS: Among p...

Descripción completa

Detalles Bibliográficos
Autores principales: Taguchi, Satoru, Onozawa, Mizuki, Hinotsu, Shiro, Kawai, Taketo, Mitomi, Takeshi, Uno, Satoshi, Kume, Haruki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550199/
https://www.ncbi.nlm.nih.gov/pubmed/37408443
http://dx.doi.org/10.1093/jjco/hyad068
_version_ 1785115483563884544
author Taguchi, Satoru
Onozawa, Mizuki
Hinotsu, Shiro
Kawai, Taketo
Mitomi, Takeshi
Uno, Satoshi
Kume, Haruki
author_facet Taguchi, Satoru
Onozawa, Mizuki
Hinotsu, Shiro
Kawai, Taketo
Mitomi, Takeshi
Uno, Satoshi
Kume, Haruki
author_sort Taguchi, Satoru
collection PubMed
description OBJECTIVE: This multicenter, retrospective, observational study investigated baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer who received primary androgen deprivation therapy, using Japan Study Group of Prostate Cancer registry data. METHODS: Among patients in the Japan Study Group of Prostate Cancer registry, those who initiated primary androgen deprivation therapy and were aged 20 years or older were enrolled in this study. The primary endpoint was time to disease progression, defined as time from primary androgen deprivation therapy initiation to either prostate-specific antigen or clinical progression. Secondary endpoints included prostate-specific antigen progression-free survival, prostate-specific antigen response (90% or greater reduction from baseline) and distribution of second-line treatment. RESULTS: Of the 2494 patients (goserelin, n = 564; leuprorelin, n = 1148; surgical castration, n = 161; degarelix, n = 621), those who received degarelix had higher prostate-specific antigen levels and Gleason scores and were at a more advanced clinical stage than those receiving goserelin or leuprorelin. The median time to disease progression (identical to the prostate-specific antigen progression-free survival result) was not reached for goserelin and leuprorelin, 52.7 months for surgical castration and 54.0 months for degarelix. Although baseline prostate-specific antigen values in the degarelix cohort were higher than those of the leuprorelin or goserelin cohorts, prostate-specific antigen responses were not different among the three cohorts. Regarding second-line treatment, the largest patient group received degarelix followed by leuprorelin (n = 195). CONCLUSIONS: This study clarified patient characteristics and long-term effectiveness of primary androgen deprivation therapy in real-world clinical practice. Japanese urologists appear to select appropriate primary androgen deprivation therapy based on patient background and tumour characteristics, with degarelix largely reserved for higher risk patients.
format Online
Article
Text
id pubmed-10550199
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-105501992023-10-05 A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy Taguchi, Satoru Onozawa, Mizuki Hinotsu, Shiro Kawai, Taketo Mitomi, Takeshi Uno, Satoshi Kume, Haruki Jpn J Clin Oncol Original Article OBJECTIVE: This multicenter, retrospective, observational study investigated baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer who received primary androgen deprivation therapy, using Japan Study Group of Prostate Cancer registry data. METHODS: Among patients in the Japan Study Group of Prostate Cancer registry, those who initiated primary androgen deprivation therapy and were aged 20 years or older were enrolled in this study. The primary endpoint was time to disease progression, defined as time from primary androgen deprivation therapy initiation to either prostate-specific antigen or clinical progression. Secondary endpoints included prostate-specific antigen progression-free survival, prostate-specific antigen response (90% or greater reduction from baseline) and distribution of second-line treatment. RESULTS: Of the 2494 patients (goserelin, n = 564; leuprorelin, n = 1148; surgical castration, n = 161; degarelix, n = 621), those who received degarelix had higher prostate-specific antigen levels and Gleason scores and were at a more advanced clinical stage than those receiving goserelin or leuprorelin. The median time to disease progression (identical to the prostate-specific antigen progression-free survival result) was not reached for goserelin and leuprorelin, 52.7 months for surgical castration and 54.0 months for degarelix. Although baseline prostate-specific antigen values in the degarelix cohort were higher than those of the leuprorelin or goserelin cohorts, prostate-specific antigen responses were not different among the three cohorts. Regarding second-line treatment, the largest patient group received degarelix followed by leuprorelin (n = 195). CONCLUSIONS: This study clarified patient characteristics and long-term effectiveness of primary androgen deprivation therapy in real-world clinical practice. Japanese urologists appear to select appropriate primary androgen deprivation therapy based on patient background and tumour characteristics, with degarelix largely reserved for higher risk patients. Oxford University Press 2023-07-05 /pmc/articles/PMC10550199/ /pubmed/37408443 http://dx.doi.org/10.1093/jjco/hyad068 Text en © The Author(s) 2023. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Taguchi, Satoru
Onozawa, Mizuki
Hinotsu, Shiro
Kawai, Taketo
Mitomi, Takeshi
Uno, Satoshi
Kume, Haruki
A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy
title A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy
title_full A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy
title_fullStr A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy
title_full_unstemmed A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy
title_short A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy
title_sort multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10550199/
https://www.ncbi.nlm.nih.gov/pubmed/37408443
http://dx.doi.org/10.1093/jjco/hyad068
work_keys_str_mv AT taguchisatoru amulticenterretrospectiveobservationalstudyinvestigatingbaselinecharacteristicsandclinicaloutcomesinpatientswithhormonesensitiveprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT onozawamizuki amulticenterretrospectiveobservationalstudyinvestigatingbaselinecharacteristicsandclinicaloutcomesinpatientswithhormonesensitiveprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT hinotsushiro amulticenterretrospectiveobservationalstudyinvestigatingbaselinecharacteristicsandclinicaloutcomesinpatientswithhormonesensitiveprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT kawaitaketo amulticenterretrospectiveobservationalstudyinvestigatingbaselinecharacteristicsandclinicaloutcomesinpatientswithhormonesensitiveprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT mitomitakeshi amulticenterretrospectiveobservationalstudyinvestigatingbaselinecharacteristicsandclinicaloutcomesinpatientswithhormonesensitiveprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT unosatoshi amulticenterretrospectiveobservationalstudyinvestigatingbaselinecharacteristicsandclinicaloutcomesinpatientswithhormonesensitiveprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT kumeharuki amulticenterretrospectiveobservationalstudyinvestigatingbaselinecharacteristicsandclinicaloutcomesinpatientswithhormonesensitiveprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT taguchisatoru multicenterretrospectiveobservationalstudyinvestigatingbaselinecharacteristicsandclinicaloutcomesinpatientswithhormonesensitiveprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT onozawamizuki multicenterretrospectiveobservationalstudyinvestigatingbaselinecharacteristicsandclinicaloutcomesinpatientswithhormonesensitiveprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT hinotsushiro multicenterretrospectiveobservationalstudyinvestigatingbaselinecharacteristicsandclinicaloutcomesinpatientswithhormonesensitiveprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT kawaitaketo multicenterretrospectiveobservationalstudyinvestigatingbaselinecharacteristicsandclinicaloutcomesinpatientswithhormonesensitiveprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT mitomitakeshi multicenterretrospectiveobservationalstudyinvestigatingbaselinecharacteristicsandclinicaloutcomesinpatientswithhormonesensitiveprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT unosatoshi multicenterretrospectiveobservationalstudyinvestigatingbaselinecharacteristicsandclinicaloutcomesinpatientswithhormonesensitiveprostatecancertreatedwithprimaryandrogendeprivationtherapy
AT kumeharuki multicenterretrospectiveobservationalstudyinvestigatingbaselinecharacteristicsandclinicaloutcomesinpatientswithhormonesensitiveprostatecancertreatedwithprimaryandrogendeprivationtherapy